Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)

NCT04665050 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infection

Interventions

BIOLOGICAL: V116
BIOLOGICAL: PNEUMOVAX™23

Sponsor

Merck Sharp & Dohme LLC